phase 3
Acadia’s pimavanserin falls short at Phase 3 in major depressive disorder
July 21, 2020Manufacturing and Production, Research and Development Acadia Pharmaceuticals, major depressive disorder, phase 3, trial failure
Acadia Pharmaceuticals has lifted the lid on new Phase 3 for its therapy pimavanserin, revealing that the drug unfortunately failed …
AstraZeneca’s trial of leukaemia drug Calquence yields positive results
December 9, 2019Sales and Marketing AstraZeneca, Calquence, leukaemia, phase 3
AstraZeneca confirmed it had recorded positive results from its Phase 3 trial of Calquence plus obinutuzumab in leukaemia. The trial …
Acadia’s schizophrenia drug flops in Phase 3 trial
July 23, 2019Manufacturing and Production acadia, clinical trials, menatl health, neuroscience, pharma, phase 3, schizophrenia
Acadia Pharmaceuticals has said its schizophrenia drug Nuplazid (primavanserin) has failed to beat placebo in a Phase 3 trial. Nuplazid …
Takeda’s Ninlaro fails to meet one of two primary endpoints in Phase 3 trial
June 6, 2019Research and Development TOURMALINE-AL1, Takeda, pharma, phase 3, trial Ninlaro
Takeda has decided to discontinue its Phase 3 study of Ninlaro (ixazomib) after the drug in combination with dexamethasone, failed …
Janssen’s Imbruvica shows superiority in Phase 3 trials
June 4, 2019Manufacturing and Production Janssen, imbruvia, leukaemia, pharma, phase 3, trial
Phase 3 data from ASCO 2019 has shown Janssen’s leukaemia drug Imbruvica (ibrutinib) had significant benefits over ofatumumab. In the …
Ibalisumab effective in in treating multidrug resistant HIV
August 16, 2018Research and Development AIDS, HIV, multidrug resistance, phase 3
The monoclonal antibody Ibalizumab has shown significant antiviral activity against multidrug resistant HIV infections, according to the results of a …
BMS pulls the plug on Phase 3 trials of IDO1 inhibitor
May 2, 2018Research and Development BMS, Bristol-Myers Squibb, IDO1, opdivo, pharma, phase 3
Bristol-Myers Squibb has terminated two pivotal Phase 3 trials of BMS-986205, an IDO1 inhibitor acquired through its $800 million acquisition …
Takeda to build €100 million dengue vaccine manufacturing plant
December 1, 2016Manufacturing and Production, Medical Communications Takeda, dengue, phase 3
Takeda have announced plans to spend more than €100 million in the construction of a new manufacturing plant in Singen, …
Darzalex meets endpoint in late-stage multiple myeloma trial
May 19, 2016Research and Development Genmab, Janssen, daratumumab, darzalex, dexamethasone, lenalidomide, phase 3, phase III, trial
Genmab has announced that positive results from a Phase III trial evaluating Darzalex (daratumumab), which is being developed in partnership …
Phase III trial meets primary endpoint for Allergan’s fibroid treatment
May 9, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, fibroid, phase 3, phase III, ulipristal, ulipristal acetate, uterine fibroid
Allergan (NYSE: AGN), in collaboration with Gedeon Richter, has announced positive results from a pivotal Phase III trial evaluating the …
Merck’s colorectal cancer drug meets primary endpoint in Phase III study
April 25, 2016Research and Development, Sales and Marketing Erbitux, Merck, Serono, cancer drugs, colorectal cancer, increased survival, oncology, phase 3, phase III
Merck (FWB: MRK) has announced that its Phase III clinical trial of Erbitux, in combination with Folfox, met its primary …
Bluebird Bio gene therapy posts encouraging results in treatment of rare brain disease
April 21, 2016Medical Communications, Research and Development Bluebird Bio, Phase II, gene therapy, lenti-d, paediatric, phase 2, phase 3, phase III, rare brain disease
Bluebird bio (NASDAQ: BLUE) has announced positive interim data from a Phase II/III trial evaluating their Lenti-D gene therapy in …
Pfizer’s cholesterol-lowering bococizumab shows promise in Phase III trials
April 1, 2016Research and Development, Sales and Marketing Pfizer, bococizumab, lipid, phase 3, phase III, spire, spire-ai
Pfizer (NYSE: PFE) has announced positive top line results from the SPIRE-AI Phase III clinical trial evaluating bococizumab. This protein …
Keryx Biopharmaceuticals announces positive Phase III study results for anaemia treatment
March 30, 2016Research and Development CKD, anaemia, chronic kidney disease, clinical trial, dialysis, keryx, keryx biopharmaceuticals, kidney, phase 3, phase III
Keryx Biopharmaceuticals (NASDAQ: KERX) has announced positive top-line results for its Phase III study of ferric citrate for the treatment …
Phase III trial initiated for enzalutamide in treatment of prostate cancer
March 24, 2016Research and Development Astellas, Medivation, arches, clinical trial, enzalutamide, phase 3, phase III, prostate cancer
Astellas Pharma (TSE: 4503) and Medivation (NASDAQ:MDVN) have announced the initiation of the ARCHES Phase III clinical trial to evaluate …
Latest content
FibroFind appoints Lee Borthwick as CEO
